A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS

Laura E. Fredenburgh(Brigham and Women's Hospital), Augustine M.K. Choi(Cornell University), Maria Pabón(Brigham and Women's Hospital), Andrew I. Sullivan(Brigham and Women's Hospital), Rie Maurer(Brigham and Women's Hospital), Eli J. Finkelsztein(Cornell University), Dean Hess(Harvard University), Mark Bouthot(Brigham and Women's Hospital), Charles N. Serhan(Brigham and Women's Hospital), Mamary Kone(Massachusetts General Hospital), Karen E. Welty‐Wolf(Duke Medical Center), Angelica Higuera(Brigham and Women's Hospital), Kiichi Nakahira(Harvard University), John Dwyfor Davies(Duke Medical Center), Joshua A. Englert(The Ohio State University Wexner Medical Center), Mark A. Perrella(Brigham and Women's Hospital), Diana Barragan-Bradford(Brigham and Women's Hospital), Mona J. Malik(Duke Medical Center), Bryan Kraft(Washington University in St. Louis), Paul B. Dieffenbach(Brigham and Women's Hospital), Claude A. Piantadosi(Duke University), Elizabeth Peters(Cornell University), David Berlin(Cornell University), Susan Lagambina(Brigham and Women's Hospital), Rebecca M. Baron(Brigham and Women's Hospital), Tilo Winkler(Massachusetts General Hospital), Paul Nuccio(Brigham and Women's Hospital), Shelley Hurwitz(Harvard University), R. Scott Harris(Massachusetts General Hospital), Bruce Thompson(The University of Melbourne), Kristen T. Schiffer(Cornell University), Clara Oromendia(Cornell University)
JCI Insight
December 5, 2018
Cited by 112


Related Papers